A randomized controlled trial found that a synbiotic supplement combining Bacillus coagulans TBC169 with fiber reduced constipation symptoms and improved bowel movements in adults over 45, though the effect came from the combined product rather than the probiotic strain alone.
Chronic constipation affects a substantial portion of the middle-aged and elderly population, creating a clinical gap: many existing treatments carry tolerability concerns or lose effectiveness with long-term use in this demographic. This 140-participant trial tested whether adding a specific probiotic strain to standard fiber supplementation could improve outcomes beyond fiber alone.
The synbiotic group (those receiving Bacillus coagulans TBC169 plus fiber) showed measurable improvements across multiple constipation metrics compared to the fiber-only control. Weekly bowel movements increased, Bristol stool scale scores improved (indicating more normal stool consistency), and validated symptom questionnaires showed reduction in constipation severity and quality-of-life impact. The Wexner score and Patient Assessment of Constipation Quality of Life (PAC-QOL) scores both favored the synbiotic group. Importantly, adverse events were mild and transient, suggesting reasonable tolerability in this age group.
The mechanistic picture emerged from post-intervention microbiota analysis. The synbiotic group showed higher gut microbial diversity (measured by Shannon and Faith_PD indices) and a distinct bacterial community composition. Several taxa differed between groups: the synbiotic group had higher relative abundance of Blautia, Akkermansia, Faecalibacterium, and Bacillus species, with lower Collinsella. These organisms are known to produce short-chain fatty acids and support intestinal function, providing a plausible biological link to symptom improvement. However, the study acknowledges a critical limitation: baseline fecal samples were not collected, meaning the microbiota findings represent exploratory between-group associations rather than definitive mechanistic evidence.
The authors emphasize an important interpretation boundary: the observed benefits should be attributed to the combined synbiotic product, not to Bacillus coagulans TBC169 in isolation. Because the formulation contained both probiotic and fiber components working together, disentangling their individual contributions from this trial design is not possible. This distinction matters for how results translate to real-world use and for understanding whether similar benefits would occur with the probiotic strain alone.
If you are middle-aged or older with chronic constipation, this trial suggests that combining a probiotic with increased fiber intake may offer symptom relief beyond fiber supplementation alone. The tolerability profile was favorable, with no serious adverse events reported. However, several practical considerations apply:
First, start with dietary fiber intake. The control group in this study received fiber supplementation, which alone produced some benefit. Increasing whole grains, vegetables, and fruits through high-fiber-diet remains a first-line approach with broad evidence support. Second, if you choose to try a synbiotic product, the evidence here specifically supports formulations containing Bacillus coagulans TBC169 combined with fiber components, not the probiotic strain alone. Third, individual responses vary: the study population was relatively homogeneous in age and geography, so results may not generalize uniformly. Finally, constipation in older adults can reflect multiple causes (medications, dehydration, reduced activity, medical conditions), so addressing underlying factors alongside supplementation makes sense.
The study also supports hydration and daily-steps-target or other movement-breaks as complementary non-pharmacological approaches, though these were not explicitly tested here.
| Parameter | Value |
|---|---|
| Design | Randomized, double-blind, placebo-controlled trial |
| Sample Size | 140 participants |
| Age | ≥45 years |
| Condition | Chronic constipation |
| Intervention | Synbiotic: Bacillus coagulans TBC169 + dietary fiber components |
| Control | Dietary fiber alone |
| Primary Outcomes | Weekly bowel movements, Bristol stool scale, Wexner score, PAC-QOL score |
| Secondary Outcomes | Gut microbiota diversity and composition, adverse events |
| Duration | Not specified in abstract |
| Publication | Biotechnology Journal |
| PubMed ID | 42226670 |
| Registry | ChiCTR2400085844 |
| Key Limitation | No baseline fecal samples collected; microbiota findings exploratory |
Biotechnology Journal. Synbiotic Supplementation With Heyndrickxia coagulans TBC169 Improves Chronic Constipation in Middle-Aged and Elderly. PubMed ID: 42226670. https://pubmed.ncbi.nlm.nih.gov/42226670/
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.